ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last3,801 to 3,820 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With at Least One On-treatment Bone Fracture Incident in the Treatment Period4 of 911

6 of 899

-0.2 points

-1.1 to 0.5

1,810NCT02345161

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With an On-treatment Penumonia Event in the Treatment Period20 of 911

7 of 899

1.4 points

0.3 to 2.7

1,810NCT02345161

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: serious adverse events61 of 911

64 of 899

-0.4 points

-2.8 to 1.9

1,810NCT02345161

A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Standard Monitor (24) vs Large Monitor (32): Polyp Detection Rate (All Indications)367 of 910

424 of 895

-7.0 points

-11.6 to -2.5

1,805NCT01952418

Effect of Video Monitor Size on Adenoma Detection Rate

Standard Monitor (24) vs Large Monitor (32): Adenoma Detection Rate (All Indications)264 of 910

271 of 895

-1.3 points

-5.5 to 2.9

1,805NCT01952418

Effect of Video Monitor Size on Adenoma Detection Rate

High Tranfusion Threshold vs Low Transfusion Threshold: deaths from any cause146 of 903

135 of 901

1.2 points

-2.2 to 4.5

1,804NCT01702805

Transfusion of Prematures Trial

LTFU (EXT2): Early Vaccination Group vs LTFU (EXT2): Catch-up Vaccination Group: LTFU (EXT2): Number of Participants Who Died5 of 936

2 of 867

0.3 points

-0.4 to 1.0

1,803NCT00090285

An Investigational Study of Gardasil™ (qHPV Vaccine) in Reducing the Incidence of Anogenital Warts in Young Men (V501-020)

dPly-PhtD Group vs Control Group: Number of Subjects With Any Serious Adverse Events (SAEs)229 of 900

232 of 903

-0.2 points

-4.3 to 3.8

1,803NCT01545375

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

dPly-PhtD Group vs Control Group: Number of Subjects With Any Acute Otitis Media (AOM) With Temporally Related Carriage338 of 900

368 of 903

-3.2 points

-7.7 to 1.3

1,803NCT01545375

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

dPly-PhtD Group vs Control Group: Number of Subjects With Any Recurrent Healthcare Provider Diagnosed Acute Otitis Media (AOM)30 of 900

32 of 903

-0.2 points

-1.9 to 1.5

1,803NCT01545375

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

dPly/PhtD Group vs Control Group: serious adverse events229 of 900

232 of 903

-0.2 points

-4.3 to 3.8

1,803NCT01545375

Evaluation of a Vaccine for Reducing Ear and Lung Infections in Children

CABG vs PCI With DES: serious adverse events391 of 897

357 of 903

4.1 points

-0.5 to 8.6

1,800NCT00114972

SYNTAX Study: TAXUS Drug-Eluting Stent Versus Coronary Artery Bypass Surgery for the Treatment of Narrowed Arteries

Greenlight Plus vs Greenlight: deaths from any cause0 of 898

2 of 902

-0.2 points

-0.8 to 0.2

1,800NCT04042467

Greenlight Plus Study: Approaches to Early Childhood Obesity Prevention

mRNA-1273.712 vs Placebo: Number of Participants With Elevated Cardiac Troponin I (cTnI) at Day 4 or Day 32 (3 Days After Injection 1 or Injection 2)1 of 890

0 of 910

0.1 points

-0.3 to 0.6

1,800NCT06634797

A Study to Investigate Cardiac Troponin Levels After mRNA-1273.712 Vaccine in Participants 12 Through 30 Years of Age

Absorb BVS vs XIENCE: Number of Cardiac Death/All MI185 of 1,187

81 of 612

2.4 points

-1.2 to 5.6

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Death (Cardiac, Vascular, Non-cardiovascular)85 of 1,187

44 of 612

-0.0 points

-2.7 to 2.4

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Participants With Target Vessel Failure (TVF)290 of 1,187

128 of 612

3.5 points

-0.6 to 7.5

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Participants With All Target Lesion Revascularization (TLR)118 of 1,187

51 of 612

1.6 points

-1.3 to 4.3

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Participants With All Revascularization255 of 1,187

114 of 612

2.9 points

-1.1 to 6.6

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Absorb BVS vs XIENCE: Number of Death/All MI/All Revascularization (DMR)378 of 1,187

168 of 612

4.4 points

-0.1 to 8.7

1,799NCT01751906

ABSORB III Randomized Controlled Trial (RCT)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=191"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=191

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT02345161-4218cf4d",
        "title": "FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With at Least One On-treatment Bone Fracture Incident in the Treatment Period",
        "summary": "4 of 911 against 6 of 899; risk difference -0.2 points, 95% interval -1.1 to 0.5; NCT02345161, A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
        "record": "/library/comparisons/NCT02345161-4218cf4d",
        "nct_id": "NCT02345161",
        "kind": "outcome",
        "participants": 1810,
        "risk_difference": {
          "value": -0.0022833029503448767,
          "lower": -0.010540854786253691,
          "upper": 0.005455422851425711
        },
        "group_1": "4 of 911",
        "group_2": "6 of 899",
        "difference": "-0.2 points",
        "interval": "-1.1 to 0.5",
        "trial_title": "A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)"
      },
      {
        "id": "NCT02345161-ecddca2d",
        "title": "FF/UMEC/VI 100/62.5/25 µg vs BUD/FOR 400/12 µg: Number of Participants With an On-treatment Penumonia Event in the Treatment Period",
        "summary": "20 of 911 against 7 of 899; risk difference 1.4 points, 95% interval 0.3 to 2.7; NCT02345161, A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)",
        "record": "/library/comparisons/NCT02345161-ecddca2d",
        "nct_id": "NCT02345161",
        "kind": "outcome",
        "participants": 1810,
        "risk_difference": {
          "value": 0.014167467450722783,
          "lower": 0.002921649465451922,
          "upper": 0.02654732502057848
        },
        "group_1": "20 of 911",
        "group_2": "7 of 899",
        "difference": "1.4 points",
        "interval": "0.3 to 2.7",
        "trial_title": "A Comparison Study Between the Fixed Dose Triple Combination of Fluticasone Furoate/ Umeclidinium/ Vilanterol Trifenatate (FF/UMEC/VI) With Budesonide/Formoterol in Subjects With Chronic Obstructive Pulmonary Disease (COPD)"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=192",
  "request_id": "yhaGtOdGncn5ymtn"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?